Brief Description
The purpose of the I CAN Study is to evaluate the safety and effectiveness of ravulizumab compared with placebo to potentially help manage symptoms in adults who have IgAN
Estimated Enrollment
470
Estimated End Date
07/2027
Trial is for people with
• Be at least 18 years of age • Have a diagnosis of IgAN based on kidney biopsy • Have been treated with stable doses of blood ...
Study Goal
Through the I CAN study, we aim to prioritize research to aid the global IgAN community.
What is involved for the patient?
Screening: Lasts approximately six weeks and includes two visits. The study team will review your medical history and perform tests to ...
About the drug or intervention
The study medication is called ravulizumab (ALXN1210). It is being used in the study for research purposes only. While ravulizumab has ...